Apnimed, Inc. Common Stock (APMD) Stock
Key stats
- Market cap
- $698.56M
- Price / Earnings ratio
- -5.2x
- EPS (TTM)
- -$23.76
- Volume
- Loading
- 52-week high
- $35.29
- 52-week low
- $13.88
Source: third-party data provider, as of November 13, 2026
Compare with APMD
Recent news

Apnimed shares surge on bullish BofA initiation
Apnimed shares surge on bullish BofA initiation
APMD

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks
Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks
APMD

Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
APMD

Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
APMD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.75
- MACD 12/26/9
- -1.44
- EMA 9 of MACD
- -1.60
- MACD histogram
- 0.16
- SMA 50
- $20.96
- Price below SMA 50
- EMA 50
- $20.52
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Apnimed shares surge on bullish BofA initiation
Apnimed shares surge on bullish BofA initiation
APMD

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks
Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks
APMD

Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
APMD

Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
APMD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Apnimed, Inc. Common Stock
Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin Robert Lind | CEO & Director | 1976 |
| Mr. Dennis Patrick Molnar M.B.A. | President & COO | 1969 |
| Mr. Michael B. Kelly | Chief Financial Officer | 1975 |
| Dr. Lawrence G. Miller M.D., M.P.H. | Founder & Vice Chair of the Board | 1954 |
| Dr. Luigi Taranto Montemurro M.D. | Co-Founder & Chief Scientific Officer | 1979 |
| Ms. Leila Sylvain | Senior Manager of Administration | — |
| Mr. Steven W. Spector J.D. | Chief Legal Officer & Head of Corporate Affairs | 1965 |
| Ms. Jennifer Patterson | Senior Vice President of Human Resources | — |
| Dr. John W. Cronin M.D. | Chief Medical Officer | 1968 |
| Dr. Sean M. Johnston M.B.A., Ph.D. | Consulting Head of CMC | 1958 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.75
- MACD 12/26/9
- -1.44
- EMA 9 of MACD
- -1.60
- MACD histogram
- 0.16
- SMA 50
- $20.96
- Price below SMA 50
- EMA 50
- $20.52
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $41.00
- Average
- $50.33
- High
- $60.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +5.0 | -18.4 | -27.2 | +9.0 |



